Michael Tollini

Cooley advised Rubrik, the Zero Trust Data Security Company delivering data security and operational resilience for enterprises, on its $752 million initial public offering. Rubrik issued and sold 23,500,000 shares of Class A common stock priced at $32 per share, with a 30-day option for the underwriters to purchase up to 3,525,000 additional shares of Class A common stock.

Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.

Cooley advised Blue Owl Capital, a top asset manager that is redefining alternatives, on its strategic investment – consisting of a nondilutive, nonrecourse royalty-backed loan of up to $140 million – in XOMA Corporation, a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.

Cooley advised Cara Therapeutics, Inc. on its $40 million royalty interest purchase and sale agreement with HealthCare Royalty Partners. Michael Tollini and Addison Pierce led the Cooley team advising Cara, which included Bin Wang, Xueqing Li and Jordan Verrilli. Cara, which trades on The NASDAQ Global Market as “CARA,” is a clinical-stage biotech company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors.

Cooley advised Beam Therapeutics, a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines, on its agreement with Verve Therapeutics to sell its opt-in rights to co-develop and co-commercialize base-editing programs for cardiovascular disease to Eli Lilly and Company.